Research analysts at B. Riley initiated coverage on shares of Agenus (NASDAQ:AGEN) in a report released on Monday, BenzingaRatingsTable reports. The brokerage set a “buy” rating and a $5.00 price target on the biotechnology company’s stock. B. Riley’s price target would suggest a potential upside of 97.63% from the company’s current price.
Several other research analysts have also recently commented on the company. Zacks Investment Research cut Agenus from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. BidaskClub raised Agenus from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. Finally, ValuEngine raised Agenus from a “hold” rating to a “buy” rating in a research report on Thursday, January 17th.
Shares of AGEN stock opened at $2.53 on Monday. Agenus has a 12 month low of $1.54 and a 12 month high of $4.13. The company has a market cap of $339.54 million, a price-to-earnings ratio of -1.76 and a beta of 2.07.
Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc raised its stake in Agenus by 47.7% during the fourth quarter. Legal & General Group Plc now owns 21,674 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 7,002 shares in the last quarter. Amalgamated Bank acquired a new position in Agenus during the fourth quarter worth $30,000. Two Sigma Securities LLC acquired a new position in Agenus during the fourth quarter worth $31,000. Vanguard Group Inc raised its stake in Agenus by 0.4% during the third quarter. Vanguard Group Inc now owns 4,360,495 shares of the biotechnology company’s stock worth $9,332,000 after acquiring an additional 18,304 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Agenus by 272.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,105 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 23,493 shares in the last quarter. 28.39% of the stock is owned by hedge funds and other institutional investors.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Read More: When is a capital gain realized?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.